Vitoc Vlad 4

What Happened

• Vitoc Vlad, CEO of MAIA Biotechnology (MAIA), received a derivative award on May 29, 2026: options covering 800,000 shares. The Form 4 reports the acquisition as a grant (transaction code A) with $0.00 listed for the acquisition amount (typical for option awards on the grant date).
• The award represents the right to purchase shares (stock options) rather than an immediate purchase of common stock. No cash value or exercise price is shown in the provided excerpt.

Key Details

• Transaction date: 2026-05-29; Form 4 filed: 2026-06-01 (filed in a timely manner).
• Transaction type/code: Grant/Award of derivative securities (code A).
• Shares/options granted: 800,000 (derivative — stock options).
• Acquisition price shown on the filing: $0.00 (grant date reporting convention).
• Vesting (per footnote): 4-year schedule — 25% vest on the first anniversary, remaining options vest ratably monthly over the following 36 months.
• Shares owned after transaction: not specified in the provided excerpt.
• No 10b5-1 plan, tax withholding, or sale/exercise details are indicated in the provided filing.

Context

• This is an option grant (a common form of executive compensation). It gives the CEO the right to buy shares in the future subject to vesting and any exercise price and plan terms; it is not an immediate purchase or sale of stock.
• Option grants are routine for executives and signal compensation alignment with long-term performance but do not alone indicate buying or selling sentiment. For full details (exercise price, total beneficial ownership after the grant), consult the complete Form 4 (Accession No. 0001878313-26-000053) on the SEC EDGAR site.